CARDIFF ONCOLOGY, INC. Increase (Decrease) in Deferred Charges
CARDIFF ONCOLOGY, INC. (CRDF) reported Increase (Decrease) in Deferred Charges of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredCharges · last filed 2020-02-27
- CARDIFF ONCOLOGY, INC. increase (decrease) in deferred charges for the quarter ending 2019-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. increase (decrease) in deferred charges for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. increase (decrease) in deferred charges for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. increase (decrease) in deferred charges for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. increase (decrease) in deferred charges for fiscal 2019 was $0.00.
- CARDIFF ONCOLOGY, INC. increase (decrease) in deferred charges for fiscal 2018 was -$59.21K, a 142.03% decline from fiscal 2017.
- CARDIFF ONCOLOGY, INC. increase (decrease) in deferred charges for fiscal 2017 was $140.86K, a 29.93% decline from fiscal 2016.
- CARDIFF ONCOLOGY, INC. increase (decrease) in deferred charges for fiscal 2016 was $201.04K.
| Period end | Increase (Decrease) in Deferred Charges 3 month | Increase (Decrease) in Deferred Charges 6 month | Increase (Decrease) in Deferred Charges 9 month | Increase (Decrease) in Deferred Charges 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $0.00 10-K · filed 2020-02-27 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | -$325.76K derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | -$325.76K derived: sum of 3 quarters · filed 2020-02-27 | -$223.05K derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-07 | -$325.76K derived: sum of 2 quarters · filed 2020-02-27 | -$223.05K derived: sum of 3 quarters · filed 2020-02-27 | -$138.79K derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-12-31 | -$325.76K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$223.05K derived: sum of 2 quarters · filed 2020-02-27 | -$138.79K derived: sum of 3 quarters · filed 2020-02-27 | -$59.21K 10-K · filed 2020-02-27 |
| 2018-09-30 | $102.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $186.97K derived: sum of 2 quarters · filed 2019-11-07 | $266.56K 10-Q · filed 2019-11-07 | $199.98K derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $84.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $163.85K 10-Q · filed 2019-08-08 | $97.28K derived: sum of 3 quarters · filed 2019-08-08 | $167.93K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $79.59K 10-Q · filed 2019-05-07 | $13.01K derived: sum of 2 quarters · filed 2019-05-07 | $83.67K derived: sum of 3 quarters · filed 2019-05-07 | $154.33K derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | -$66.57K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $4.09K derived: sum of 2 quarters · filed 2019-03-06 | $74.74K derived: sum of 3 quarters · filed 2019-03-06 | $140.86K 10-K · filed 2019-03-06 |
| 2017-09-30 | $70.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $141.32K derived: sum of 2 quarters · filed 2018-11-07 | $207.44K 10-Q · filed 2018-11-07 | $275.09K derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | $70.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $136.78K 10-Q · filed 2018-08-03 | $204.44K derived: sum of 3 quarters · filed 2018-08-03 | |
| 2017-03-31 | $66.12K 10-Q · filed 2018-05-08 | $133.78K derived: sum of 2 quarters · filed 2018-05-08 | ||
| 2016-12-31 | $67.66K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $201.04K 10-K · filed 2018-02-26 | ||
| 2016-09-30 | $133.38K 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |